Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy-Reference-Cited by-同舟云学术

Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy

Published:2021-02-24 Issue:7 Volume:12 Page:997-1005
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Qian Li¹^ORCID,Zhaohui Zhang¹,Yaping Xu¹,Zhentian Liu¹,Zhentao Liu¹,Qiqi Wang¹,Yangchun Gu¹,Yan'e Liu¹,Wencheng Yin¹,Fumei Yi¹,Yanhong Yao¹,Baoshan Cao¹,Li Liang¹

Affiliation:

1. Department of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13771

Reference41 articles.

1. Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells

2. Trial watch: Immunogenic cell death inducers for anticancer;Pol J;Chemotherapy,2015

3. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer;Schaer DA;Immunotherapy,2019

4. Recent advances in targeting CD8 T‐cell immunity for more effective cancer;Durgeau A;Immunotherapy,2018

5. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy;ESMO Open;2023-12